Kodak execs didn't illegally trade stock while touting big move into pharma: report

Eastman Kodak's pharma ambitions took a hit when insider trading accusations put $765 million in U.S. funding on the skids. But a special committee hired by Kodak's board has now cleared its top brass of wrongdoing—a decision that could clear its path into drug manufacturing.

The board-appointed committee cleared (PDF) Kodak's executives and shareholders of insider trading after a series of questionable stock moves that followed a government loan agreement. That $765 million loan has since been suspended.